Thank you.
If I could just add, sir, with respect to joint reviews, you mentioned the joint review opportunities that we now have with Australia, with Europe, Austria. We're currently doing those joint reviews for brand new chemicals. It's interesting that the manufacturers of those brand new chemicals are able to put together one single package of data and information, not only for Canada, the United States, and Europe, but sometimes for Australia.
In those situations they're adding some additional information to cover off specific regional environment needs that Europe may have or that Canada might have or that the United States might have, and that occurs for both environment and efficacy.
From a human toxicology standpoint, that is largely harmonized to the extent where most countries are asking for essentially all the same information.
We've done a substantial amount of work over the last five or ten years in harmonizing the kind of information we have. So in terms of your question of what we can focus on, through both our work at NAFTA and through the OECD, we have narrowed down to some of those key things that can still make a difference between whether chemicals can come to one country or another or whether they might serve as an impediment to a manufacturer coming to Canada.
The number of those differences is getting very small.